EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study

Pou Hong Justin Chia, Takuya Toyonaga iD, Junchao Tong iD, Hannah Le, Mark Dias, Amanda J Boyle iD, Roger Raymond, Erin E Longbrake, Yiyun Huang iD, Richard E Carson iD, Laura Airas, Neil Vasdev iD und 2 weitere

Proceedings of the National Academy of Sciences · 10.03.2026 · 123 (10)

DOI: 10.1073/pnas.2517709123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.03.2026. Verfasst von Pou Hong Justin Chia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Ment…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Membrane Glycoproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), Michael J. Fox Foundation for Parkinson's Research (MJFF), Michael J. Fox Foundation for Parkinson’s Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synaptic loss is increasingly recognized as a key pathological feature in multiple sclerosis (MS), contributing to disease progression and cognitive dysfunction. Synaptic vesicle glycoprotein 2A (SV2A) positron emission tomography (PET) imaging has emerged as a promising tool for quantifying synaptic density in vivo. Here, we used the clinically translatable tracer [ 18 F]SynVesT-1 to comprehensively characterize synaptic density across the brain and spinal cord in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. In parallel, we performed SV2A PET in patients with MS using the first clinically implemented SV2A radiotracer, [ 11 C]UCB-J, providing cross-species validation of SV2A PET imaging as a biomarker of synaptic pathology. In EAE mice, dynamic [ 18 F]SynVesT-1 PET imaging revealed a significant global reduction in tracer uptake, with nearly 30% decrease in regional distribution volume ( V T ) across all analyzed brain regions ( P < 0.0001). Correspondingly, autoradiography (ARG) corroborated the PET findings, and additional analyses demonstrated reduced SV2A levels in the cervical and lumbar spinal cord. In a clinical PET research study, [ 11 C]UCB-J imaging in MS patients (n = 6) versus age-matched healthy controls (n = 6) showed a 16.4% reduction in global cortical SV2A binding ( P = 0.026), with significant regional reductions of 16 to 26% in several cortical and subcortical subregions. Together, these findings demonstrate that SV2A PET imaging provides a sensitive and quantitative biomarker of synaptic pathology in MS. The consistent reductions in SV2A binding observed in both preclinical and clinical research highlight the role of synaptic degeneration in MS and underscore the utility of SV2A PET imaging in MS research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyEncephalomyelitis, Autoimmune, ExperimentalMultiple SclerosisMembrane GlycoproteinsNerve Tissue ProteinsSynapsesAnimalsHumansFemaleMicePilot ProjectsAdultSpinal CordBrainMice, Inbred C57BLMiddle AgedMale

Stichwörter der Autor:innen

multiple sclerosispositron emission tomographysynaptic densitysynaptic vesicle glycoprotein 2Atranslational

Substanzen

Membrane GlycoproteinsNerve Tissue ProteinsSV2A protein, humanSv2a protein, mouse

Autor:innen und Institutionen

  • Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON M5T 1R8, Canada.
  • Department of Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5G 2C8, Canada.
  • Department of Radiology and Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT 06520.
  • Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5T 1R8, Canada.
  • Department of Neurology, Yale School of Medicine, Yale University, New Haven, CT 06520.
  • Neurocenter, Turku University Hospital, University of Turku, Turku 20521, Finland.

ORCID-Profile: Takuya Toyonaga, Junchao Tong, Amanda J Boyle, Yiyun Huang, Richard E Carson, Neil Vasdev, Ming-Kai Chen, Chao Zheng

Förderung

  • Canadian Institutes of Health Research (CIHR)
  • Michael J. Fox Foundation for Parkinson's Research (MJFF)
  • Michael J. Fox Foundation for Parkinson’s Research

Zitieren

APA

Chia, P. H. J., Toyonaga, T., Tong, J., Le, H., Dias, M., Boyle, A. J., Raymond, R., Longbrake, E. E., Huang, Y., Carson, R. E., Airas, L., Vasdev, N., Chen, M. K., & Zheng, C. (2026). SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study. Proceedings of the National Academy of Sciences, 123(10). https://doi.org/10.1073/pnas.2517709123

Vancouver

Chia PHJ, Toyonaga T, Tong J, Le H, Dias M, Boyle AJ, et al. SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study. Proceedings of the National Academy of Sciences. 2026;123(10). doi:10.1073/pnas.2517709123

BibTeX
@article{Chia2026,
  author = {Chia, Pou Hong Justin and Toyonaga, Takuya and Tong, Junchao and Le, Hannah and Dias, Mark and Boyle, Amanda J and Raymond, Roger and Longbrake, Erin E and Huang, Yiyun and Carson, Richard E and Airas, Laura and Vasdev, Neil and Chen, Ming-Kai and Zheng, Chao},
  title = {SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {10},
  doi = {10.1073/pnas.2517709123}
}
Kostenlos starten →